Dmytro Aleshko, managing partner with Legal Alliance law firm, joined the 4th National Forum on Health Technology Assessment: Moving to the Next Level of HTA Implementation. Dmytro moderated a panel discussion "Review of the road map of HTA in Ukraine". Brad Groves, director of NICE Scientific Advice (Great Britain), and Oleksandr Bondar, counsel with Legal Alliance joined the discussion as speakers.
The discussion was enhanced by contribution of: Oleksandr Hrytsenko, deputy head of the Pharmaceutical Department of the Ministry of Health of Ukraine; Prof. Kostyantyn Kosyachenko, advisor to the State Expert Center; Prof. Oleksandra Oleschuk, head of the department of clinical pharmacology of the Ternopil National Medical University; Natalia Babak, co-chair of the Healthcare Committee of the American Chamber of Commerce in Ukraine; and Oksana Aleksandrova, chairman of the board of PHA Ukraine.
"Despite the continuous missile attacks on the capital of Ukraine, the Fourth National Forum on Health Technology Assessment was held in Kyiv. The level of discussion on a regulation of HTA has shown remarkable growth over the last two years, as noted by the participants. In a few years, Ukraine has gone through the process of building the HTA landscape, which other countries have gone through for decades," – commented Dmytro.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
